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Abstract: The worldwide introduction of the ﬁ  rst, unique patch for hormonal contraception 
(ethinyl estradiol/norelgestromin, EE/NGMN patch) was widely recognized as a signiﬁ  cant event 
in the development of drug delivery systems. This innovation offers a number of advantages 
over the oral route, and extensive clinical trials have proved its safety, efﬁ  cacy, effectiveness, 
and tolerability. The weekly administration and ease of use/simplicity of the EE/NGMN patch 
contribute to its acceptability, and help to resolve the two main problems of non-adherence, 
namely early discontinuation and inconsistent use. The patch offers additional beneﬁ  ts to adoles-
cents (improvement of dysmenorrhea and acne), adults (improvement in emotional and physical 
well-being, premenstrual syndrome, and menstrual irregularities), and perimenopausal women 
(correction of hormonal imbalance, modulation of premenopausal symptoms), thus providing 
high satisfaction rates (in nearly 90% of users). Since its introduction, the transdermal contra-
ceptive patch has proved to be a useful choice for women who seek a convenient formulation 
which is easy to use, with additional, non-contraceptive tailored beneﬁ  ts for all the ages.
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Introduction: transdermal drug delivery
Patient adherence is a key issue that must be addressed to ensure the efﬁ  cacy of 
hormonal contraception. Combined hormonal contraceptives are effective forms of 
reversible contraception, whose beneﬁ  ts have been established by a wealth of studies 
(D’Souza and Guillebaud 2002; Petitti 2003). Provided that they are taken regularly 
and correctly on a once-daily regimen, combined hormonal contraceptives are more 
than 99% effective and almost 100% reliable, the ﬁ  rst-year pregnancy rate being less 
than 0.5% among perfectly conscientious users (Potter et al 1996). However, from 
19% to 47% of oral contraceptive users miss one or more pills per cycle (Pierson 
et al 2003) and this gap translates into thousands of unintended pregnancies annually 
(Archer et al 2002). A more convenient method of administration has thus been sought, 
to reduce the risk of “missing pills”.
Transdermal systems represent a milestone innovation in drug delivery, offer-
ing a number of advantages over the oral route (Prausnitz et al 2004), They include 
multiday and more convenient dosing, especially for the sustained release of short 
half-life drugs (Burkman 2007). The main drawback of this technology is that only a 
limited number of drugs can be delivered by passive diffusion from a patch, because 
low molecular weight, high lipophilic property, and a small required dose are essential 
for a molecule to permeate the skin (Burkman 2007). Thus the introduction of the ﬁ  rst, 
unique patch for transdermal hormonal contraception (ethinyl estradiol/norelgestromin, 
EE/NGMN patch) was widely acknowledged as a signiﬁ  cant step in the development 
of transdermal drug delivery (Prausnitz et al 2004).Patient Preference and Adherence 2008:2 358
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The central aim of this article is to review the main 
evidence supporting the use of the transdermal contraceptive 
EE/NGMN patch, with particular reference to patient 
adherence and satisfaction.
Methods
A Medline search was made during April 2008, to identify all 
types of articles in English on the EE/NGMN patch, including 
prospective open label and controlled clinical studies. The 
keywords were: “transdermal”, “contraceptive”, “ethinyl 
estradiol”, “norelgestromin”, “compliance”, “adherence”, 
“persistence”, “acceptability”, “therapeutic alliance”, and 
“patient satisfaction”. Congress communications on the 
same topics were also searched, to include more recent 
clinical studies. When no refererences are cited, the reader 
can assume that the author’s clinical observations are 
presented.
Main characteristics and clinical 
development
The EE/NGMN patch is an innovative, three-layer hormonal 
contraceptive system that provides similar efﬁ  cacy to oral 
contraceptives, with the substantial beneﬁ  t of once-weekly 
administration. The patch is applied once weekly for 3 con-
secutive weeks, followed by a patch-free week. As a result, 
users need only actively comply with dosing once weekly 
on the same day (Pierson et al 2003).
The transdermal contraceptive EE/NGMN patch has the 
same mechanisms of action as combined oral contracep-
tives. After the patch is applied, hormones appear rapidly 
in the circulation, reaching a plateau after approximately 
48 hours, which is maintained at this level during the 7-day 
wear period. On average, each EE/NGMN patch delivers 
150 μg of norelgestromin (the primary active metabolite 
of norgestimate) and 20 μg of ethinyl estradiol daily to the 
systemic circulation (O’Connel and Burkman 2007).
The pharmacokinetic properties (Abrams et al 2001; 
Burkman 2007) of the EE/NGMN transdermal patch 
provide particular beneﬁ  ts over combined oral contracep-
tives (Table 1).
Efﬁ  cacy
Three pivotal phase III clinical studies have consistently 
conﬁ  rmed the contraceptive efﬁ  cacy of the transdermal EE/
NGMN patch, either in comparison with oral contraceptives 
(Hedon et al 2000; Audet et al 2001) or according to an open, 
non-comparative trial design (Smallwood et al 2001).
Pooled analyses of pivotal trials on more than 3,300 women 
and more than 22,000 treatment cycles showed favorable 
results: the EE/NGMN patch had an overall annual prob-
ability of pregnancy (method failure plus user failure) of 
0.8% and a method failure probability of 0.6%. Efﬁ  cacy 
and cycle control were similar to those of established oral 
contraceptives, and were comparable across age and racial 
groups (Zieman et al 2002). Follicular size and incidence of 
ovulation proved to be signiﬁ  cantly reduced among patch 
users compared with those in women using oral contracep-
tives, both in normal cycles and after planned dosing errors 
(Pierson et al 2003).
Besides controlled studies, effectiveness was tested in real 
life conditions. Results of a large European, open-label study 
evaluating women’s experience with the transdermal contra-
ceptive patch during routine use were recently disclosed at a 
congress (Jakimiuk et al 2006a; Jakimiuk et al 2006b). In the 
study, 573 healthy women were followed up for six, 4-week 
treatment cycles. The transdermal contraceptive patch was 
shown to be a reliable method of contraception, with a Pearl 
Index (the number of pregnancies per 100 women-years 
Table 1 Clinical advantages of a transdermal system for contraception
Allows longer, multiday, more convenient dosing intervals than the once daily administration of oral contraceptives (Burkman 2007)
Improves patient compliance (Abrams et al 2001)
Can reduce side effects by avoiding peak high concentrations and ensuring continuous, sustained hormonal release (Abrams et al 2001)
Avoids ﬁ  rst-pass liver metabolism, thus enabling the use of lower doses to achieve efﬁ  cacy and reducing the chances of drug interactions 
(Abrams et al 2001)
Unaffected by bouts of vomiting and/or diarrhea, which prevent adequate absorption by the gut (Abrams et al 2001)
Can easily be withdrawn if necessary (Burkman 2007)
More forgiving of dosing errors: back up contraception not needed if patch change is forgotten for 1–2 days in the middle of a 4-week cycle (weeks 2 and 3) 
(Abrams et al 2001)
Eases compliance of use in cases of jet-lag and frequent ﬂ  ying
Allows safe administration in women with lactose and gluten intolerancePatient Preference and Adherence 2008:2 359
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of use) of 0.43 (95% CI: –0.41 to 1.27) and a Pearl Index 
for patients who reported perfect compliance of 0.48 (95% 
CI: –0.47 to 1.43). Thus both indexes were comparable to 
those of other popular forms of hormonal contraception.
A further study (Sonnenberg et al 2005) estimated the 
contraceptive effectiveness of the patch versus oral contra-
ceptives in real life conditions. The probability of pregnancy 
with the transdermal patch was shown to be lower than with 
oral contraceptives in all age groups, included younger 
women (Figure 1). Therefore, the effectiveness of the patch 
is expected to exceed that of oral contraceptives, due to an 
increased rate of perfect use.
Adhesion could be a potential concern, because optimal 
drug delivery can be achieved only if the patch remains 
adhered to the user’s skin. In fact the adhesive reliability 
of the contraceptive patch has proved to be excellent and 
consistent: the two clinical trials showed that only 1.8% 
and 2.9% of patches required replacement because of com-
plete or partial detachment, respectively. Furthermore, it 
was observed that patch adhesion tended to improve over 
treatment cycles, probably because participants learned the 
proper application technique with continued use. Finally, 
speciﬁ  c studies showed that the contraceptive patch detach-
ment rate was unaffected by heat, humidity, and exercise 
(Zacur et al 2002).
In conclusion, the EE/NGMN patch provides, on a once-
weekly schedule, at least the same efﬁ  cacy as marketed oral 
contraceptives administered on a daily regimen, with the 
added beneﬁ  ts of sustained hormone concentrations and 
greater “forgiveness” of dosing errors. Even if a scheduled 
patch change is missed for 2 days during weeks 2 and 3 of 
a 4-week cycle, clinical efﬁ  cacy is maintained, and backup 
contraception is not needed (Burkman 2007). Adhesion 
properties are reassuring for women who enjoy participat-
ing in exercise, as they can maintain all their usual activities 
including bathing, swimming, jogging, and using a whirlpool 
or a sauna (Abrams et al 2001; Zacur et al 2002).
Tolerability and safety
The pooled analysis of safety and tolerability data across 
three pivotal studies showed that the adverse effect proﬁ  le 
of the EE/NGMN patch was fairly similar to that of oral 
contraceptives, the most frequent adverse events being 
headache and nausea (Figure 2). A few notable differences 
were reported in patch users: transient, mild to moderate 
application site reactions, as expected, and breast discomfort 
symptoms, which generally resolved after 3 months of use. 
Local tolerability was shown to be good, with low potential 
for irritation and no potential for photo-toxicity (Sibai et al 
2002). However, women with atopia and allergic skin dis-
eases are more vulnerable to allergic reactions or local skin 
irritation.
Further studies addressed some safety issues and showed 
that oral and transdermal contraception with similar hormones 
induced similar effects on vascular risk markers (Johnson et al 
2008; Kluft et al 2008). A review of post-marketing safety and 
surveillance data for progestin oral contraceptives containing 
norgestimate and ethinyl estradiol provided useful informa-
tion about the relative rate of vascular events (Lippman and 
Shangold 1997). These data fully supported the favorable 
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cardiovascular safety proﬁ  le of norgestimate-containing 
oral contraceptives. A recently published, nested, case-
control, epidemiologic study, which compared different 
routes of administration, and included a further 17 months 
of follow up, showed that the risk of non-fatal venous 
thromboembolism was similar in the contraceptive patch 
and norgestimate-containing oral contraceptives with 35 μg 
of ethinyl estradiol (Jick et al 2006; Jick et al 2007). Fur-
thermore, the EE/NGMN patch showed no evidence of an 
increased risk of cerebral venous sinus thrombosis compared 
with levonorgestrel-containing, norgestimate-containing, 
and desogestrel-containing oral contraceptives (Jick and 
Jick 2006). Moreover, ischemic stroke and acute myocardial 
infarction were rarely reported among contraceptive patch 
users (Jick and Jick 2007). Only one epidemiologic study 
reported a more than two-fold increase in the risk of venous 
thromboembolism, but not arterial thromboembolic events, 
for the transdermal contraceptive system, compared with the 
same risk in users of norgestimate-containing oral contracep-
tives (Cole et al 2007). These data were not conﬁ  rmed by 
other studies; moreover, the estimated incidence of venous 
thrombo-embolism per 100,000 women-years was 40.8 for 
contraceptive patch users, which is similar to that reported in 
studies of third generation progestins (Burkman 2007).
Therefore the EE/NGMN contraceptive patch experience 
conﬁ  rms previously reported ﬁ  ndings on safety in hormonal 
oral contraceptives: provided that they are not prescribed to 
women at risk, and that they contain a low dose of ethinyl 
estradiol and suitable progestins (eg, norgestimate), their net 
health beneﬁ  t is great, even when the health risks are taken 
into account (Petitti 2003).
Perfect dosing
Patch users were better able to follow the dosing regimen than 
users of daily oral contraceptive (Creasy et al 2001). Indeed 
transdermal contraception has been shown to improve the 
percentage of cycles with perfect dosing compared with oral 
contraceptives. Pooled data across the three pivotal studies 
showed that the percentage of cycles with perfect dosing was 
signiﬁ  cantly higher with the patch than with oral contracep-
tives (Archer et al 2004).
Age has often been reported as a factor affecting correct 
and consistent oral contraceptive use. Signiﬁ  cantly, in the 
main comparative clinical trial conducted in North America, 
perfect use was consistent across age groups for the patch, 
while, as expected, rates of perfect use for oral contraceptives 
differed signiﬁ  cantly by age (Archer et al 2002). Adolescents 
(the age group most vulnerable to forgetting to take oral con-
traceptives and/or unintentional mistakes and thus inadequate 
adherence) had the greatest increase in compliance with 
transdermal contraception over oral contraceptives (87.7% 
vs 67.7%) (Audet et al 2001). This signiﬁ  cant advantage 
should be considered especially when counseling adolescents 
on contraceptive choices.
As a consequence of improved compliance, a base-case 
analysis showed that increased perfect use of the patch would 
result in a saving of US$249 per woman over 2 years com-
pared with oral contraceptives (Sonnenberg et al 2005).
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Transdermal contraception has further beneﬁ  ts, encouraging 
perfect use, in addition to its effectiveness in preventing unwanted 
pregnancies and its favorable safety proﬁ  le. Most women 
consider the patch a convenient and simple method: in a 
recent study, more than 70% preferred or strongly preferred 
this contraceptive method compared with previous forms of 
contraception (Jakimiuk et al 2006b, Table 2). Convenience 
and simplicity of use were predominant factors in this high 
level of preference and contributed to the good acceptability 
of the patch.
Patient adherence and acceptability
When considering patient choices among contraceptive meth-
ods, the reasons for treatment compliance and adherence need 
to be carefully considered. As originally deﬁ  ned by Sackett 
in his 1976 landmark publication (Sackett et al 1976), the 
term compliance refers to the extent to which the behavior 
of the patient coincides with the doctor’s order. The term 
compliance has long been criticized as denoting obedience 
by passive patients to doctors as authoritity ﬁ  gures, in the 
traditional hierarchical doctor/patient relationship. There-
fore, a more consistent deﬁ  nition encompassing consensus 
was sought.
Adherence can also refer to a therapeutic plan, mutually 
agreed between patient and doctor, in which the patient 
expects to understand the information provided, and to 
co-operate by adding their personal perception and experience 
(Probstﬁ  eld 1991). Because they actively “adhere” to thera-
peutic decisions, patients are involved in mutual decision 
making with their doctor, reaching a “therapeutic alliance”, 
a valuable predictor of favorable outcome.
However, adherence needs to be combined with 
persistence for the duration of treatment, to optimize efﬁ  cacy 
and satisfaction with use. In this way, personal reward, can 
encourage repetition of the same behavior.
The major difference detected in the oral contraceptive 
failure rate with perfect use (0.1%), and the failure rate in real 
life (6.9% after 12 months) probably reﬂ  ects at least some 
degree of dissatisfaction with available methods (Trussel and 
Vaughan 1999). Every physician prescribing a contraceptive 
should carefully evaluate patient satisfaction, and factors 
that could potentially enhance it. This satisfaction is closely 
related to the success of treatment, just as a favorable patient/
physician relationship inﬂ  uences treatment adherence. Oral 
contraceptive non-adherence can be explained in several 
ways, that is, early discontinuation (drop-outs), sporadic 
non-adherence due to forgetfulness and/or unintentional 
mistakes (inconsistent use), and systematic non-adherence 
over time (Table 3).
Early discontinuation is the most critical issue, as women 
who discontinue oral contraceptives often choose a less reli-
able contraceptive or no method at all, thus experiencing 
more unintended pregnancies. A signiﬁ  cant predictor of early 
discontinuation is the occurrence of adverse events, with an 
increased risk of discontinuation as the number of adverse 
effects increases (Rosenberg et al 1995). Weight gain is the 
most commonly reported adverse event leading to drop out. It 
seems to be a subjective complaint, however, as no evidence 
of a causal association between hormonal contraception and 
weight gain was found by the Cochrane group in their recent 
systematic review (Gallo et al 2006).
Key predictors for inconsistent use are lack of an estab-
lished routine for pill-taking and failure to understand instruc-
tions, thus emphasizing that quality of information provided 
by the physician and mutual decision making are inﬂ  uential 
in achieving long-term adherence.
As shown by measuring compliance using electronic 
devices, women tend to become less careful about their 
pill-taking behavior over time (Potter et al 1996). This 
change may reﬂ  ect personalized schedules of use, learning 
to make up for occasional missed pills, or a kind of fatigue 
during continuous use. In addition, the same study showed 
that women tend to under-report their missed pills: the 
proportion of women missing at least three pills in a cycle 
according to the electronic data was triple that derived from 
the women’s diaries (30%–51% vs 10%–14%). Missing 
pills were more likely to be clustered at the weekends and 
Table 2 Satisfaction, compliance and preference for the patch
573 women aged 18–46 years were enrolled to use the patch for six 4-week 
treatment cycles. In total, 467 women (81.5%) completed the study. Most 
women (410, 71.5%) had been using a contraceptive method before the 
start of the study (Jakimiuk et al 2006b).
At baseline
Satisfaction with their previous method of contraception 56.2%
Oral contraceptive users reported missing doses (some, 
most, or all of the time)
38.7%
After using transdermal contraception (6 cycles)
Satisfaction
 Satisﬁ  ed or very satisﬁ  ed with the patch 88%
  Find the patch convenient or very convenient 90%
Compliance
  Cycles with perfect compliance 89.5%
Preference or strong preference for the patch
 Shift  from  oral contraception 67.5%
  Shift from barrier contraception 84.8%Patient Preference and Adherence 2008:2 362
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on consecutive days (Potter et al 1996), with a consequent 
increased risk of irregular bleeding and unintended preg-
nancies.
An analysis of women’s self described reasons for miss-
ing pills showed that the three most reported reasons were 
being away from home, simply forgetting to take a pill, and 
not having the pill pack with them/being unable to obtain a 
new pack of pills in time for the beginning of the new cycle 
(Smith and Oakley 2005). Further predictors for inconsistent 
use are reported in Table 4.
To date, systematic “reasoned” non-adherence, whereby 
patients decide to change the dosage and/or dosing interval 
without informing the doctor, does not seem to have been 
adequately investigated. This kind of non-adherence can 
be avoided to some extent, by jointly establishing the ulti-
mate objective, which differs according to the age of the 
woman. Evaluating a woman’s particular needs or speciﬁ  c 
fears (including fear of forgetting to taking the pill, or fear 
of a negative effect on the body) and other such emotions 
including general anxiety which could foster inconsistent 
usage (Walsemann and Perez 2006) can help in doctor/
patient decision making. In a recent cross-sectional mul-
ticenter study, designed to assess the reasons for selecting 
the contraceptive pill, the skin patch, or the vaginal ring in 
9700 women, the main reasons for choosing one type of 
hormonal treatment over another, consistent with the ﬁ  ndings 
of previous studies, were convenience and frequency of use 
associated with lower probability of inadvertent omission 
(Lete et al 2007). In addition, including the husband in family 
planning programs has been shown to increase the use of 
modern contraception (Terefe and Larson 1993).
Adherence to treatment has been shown to be statisti-
cally superior for the transdermal patch compared with 
that observed with oral contraceptives (Figure 3), in all 
age groups (Archer et al 2004) and in all treatment cycles 
(Dittrich et al 2002). The same is true for user satisfaction: 
in a study presented at a recent conference (Jakimiuk et al 
2006b), the mean satisfaction score was shown to increase 
Table 4 Key predictors for inconsistent contraceptive use
Country of residence: signiﬁ  cant differences among countries may reﬂ  ect cultural differences, problem/free access to contraception, or different 
counseling attitudes
Low income: higher risk of contraceptive failure and lower likelihood of resuming contraceptive use, possibly due to education problems
Age: very young women are more likely to be inconsistent users than older women (Pons 2006)
Problems with access: difﬁ  culties in obtaining the contraceptive (Westhoff et al 2007)
Insufﬁ  cient involvement of the partner (Terefe and Larson 1993)
Lack of contraceptive knowledge or negative experience with the contraceptive method (both associated with more requests for abortion) 
(Rasch et al 2007)
Table 3 Main determinants of compliance, adherence, and persistence
Compliance Adherence Persistence
Early 
discontinuation
Inconsistent usage Systematic “reasoned”
non-adherence
Quality of doctor/patient 
relationship (Probsﬁ  eld 1991)
Inconvenient usage 
(WHO 2003)
No established routine for 
intake (Rosenberg et al 1998)
Poor quality of doctor/
patient relationship 
(RamaRao et al 2003)
Mutual decision making that 
leads to rewards in the form 
of personal need satisfaction 
(Cramer et al 2008)
Active involvement of woman 
(Probsﬁ  eld 1991)
Undesirable effects 
(WHO 2003)
Did not read or understand 
package leaﬂ  et (Rosenberg 
et al 1998)
Couple conﬂ  icts 
(Miller 1986)
Active involvement of partner 
(Probsﬁ  eld 1991)
Inadequate instructions by 
doctor (Rosenberg et al 1998)
Inconvenient usage (Rosenberg 
et al 1998)
Undesirable effects (Rosenberg 
et al 1998)
Negative partner attitude 
towards hormonal contracep-
tion (Terefe and Larson 1993)Patient Preference and Adherence 2008:2 363
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when women switched from previous contraceptive methods 
to the transdermal patch (Table 2).
Furthermore, in a recently published Cochrane review 
comparing contraceptive effectiveness and compliance in 
non-oral methods versus oral contraceptives, the authors 
concluded that although effectiveness was similar, the con-
traceptive patch group reported better compliance than the 
oral contraceptive group (odds ratio = 2.05 and 2.76 in two 
trials). In one crossover ring trial greater non-compliance 
was reported by ring users (Lopez et al 2008).
Beneﬁ  ts of hormonal contraception: 
tailoring treatment
Today women are still largely unaware of the non-
contraceptive health benefits associated with hormonal 
contraceptives (Table 5). Choosing a contraceptive 
method is a mutual decision that should take into account, 
besides the risks, the expected non-contraceptive beneﬁ  ts. 
A doctor should evaluate these with the woman in order to 
agree on a tailored program to achieve her adherence and 
persistence of use.
Adolescents
The most popular form of birth control among adolescents 
is oral contraceptives (Rubinstein et al 2004). However, 
adolescents tend to miss oral contraceptive pills, with a rate 
of failure close to 5% to 18%, that is, approximately 55% 
higher than that found in adult users, leading to a greater 
risk of unintended pregnancies (Rubinstein et al 2004; 
Harel et al 2005). In addition, less than 60% of adolescents 
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Table 5 Well-established non-contraceptive beneﬁ  ts of hormonal methods
Beneﬁ  t Mechanism
Relief of dysmenorrhea Reduction of prostaglandin levels in menstrual ﬂ  uid (French 2008); 
reduction of heavy periods; symptomatic treatment of endometriosis
Prevention of ovulation pain Inhibition of ovulation (Jensen and Speroff 2000)
Contribution to the resolution of iron-deﬁ  ciency anemia Reduction of blood loss and heavy periods (Petitti 2003)
Treatment of polycystic ovary syndrome Inhibition of ovarian activity; reduction of androgen excess; regulation 
of menstrual cycles (Yildiz 2008)
Treatment of endometriosis Down regulation of the hypothalamus-pituitary-ovarian pathway (Rodgers 
and Falcone 2008); reduced stimulation of endometrial ectopic tissue
Reduction of the risk of endometrial cancer Progestin-mediated suppression of estrogen-induced proliferation 
of endometrial cells (Petitti 2003; Hannaford et al 2007)
Reduction of the risk of ovarian cancer Suppression of ovulation (suggested) (Petitti 2003; Hannaford et al 2007; 
Collaborative Group on Epidemiological Studies of Ovarian Cancer 2008)Patient Preference and Adherence 2008:2 364
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report perfect compliance with oral contraceptives, the rate 
of discontinuation within 1 year being approximately 64% 
(Rubinstein et al 2004).
A number of speciﬁ  c studies have examined adolescent 
use of the transdermal EE/NGMN contraceptive patch, 
conﬁ  rming that it can provide a convenient form of revers-
ible contraception (Logsdon et al 2004). Its ease of use 
and the fact that it does not require daily attention are well 
acknowledged by adolescents who have used it (Rubinstein 
et al 2004).
The ﬁ  nding that users of the transdermal EE/NGMN 
contraceptive patch generally experience minimal changes 
in body weight could be relevant to adolescent use, because 
weight gain is a signiﬁ  cant predictor of early discontinuation 
of combined hormonal contraceptives in this age subgroup 
population (Harel et al 2005).
Improvement of facial acne, relief of dysmenorrheal 
symptoms, and reduction of heavy periods are further ben-
eﬁ  ts. In a recent study of Thai adolescent women, participants 
reported a decrease in dysmenorrhea, shorter duration of 
bleeding, and an improvement of facial acne (Piyasirisilp and 
Taneepanichskul 2008). These data conﬁ  rm the previously 
reported ﬁ  ndings of Harel’s study, that is, an improvement 
in the facial acne of one third of adolescents, and favorable 
results in a preliminary study of patch use among women 
suffering from papulo-pustular inﬂ  ammatory acne. Clinical 
improvement started from the fourth month, with lesions 
almost disappearing in some patients (Caputo et al 2005). 
Furthermore, in women with acne vulgaris, an oral contracep-
tive containing norgestimate has been shown to be effective 
in normalizing skin-surface lipids in seborrheic areas, while 
skin hydration did not undergo any important changes (Sator 
et al 2003).
These therapeutic effects have been ascribed to the 
progestin component of the patch, which interacts selec-
tively with the progesterone receptor and, therefore, does 
not stimulate androgen receptors (White et al 2005). 
Norgestimate, which is metabolized to norelgestromin, has 
negligible binding afﬁ  nities for the androgen receptor and 
for the sex hormone-binding globulin (SHBG), reﬂ  ecting 
the low androgenicity of this progestin, which is a desirable 
property particularly when signs of skin hyperandrogen-
ism such as acne appear. In addition, the antiandrogenic 
activity of norgestimate and of norelgestromin has recently 
been demonstrated, using a human androgen-dependent 
stable-transfected cell line (Paris et al 2007). Finally, in skin 
tissue, norgestimate is a potent inhibitor of 5α-reductase, 
the enzyme responsible for transforming testosterone in the 
more potent 5α-dihydrotestosterone (Rabe et al 2000). Given 
these ﬁ  ndings, the contraceptive EE/NGMN patch could be 
useful in women with disorders of androgen excess (White 
et al 2005).
Adult women
Some evidence indicates that the patch is particularly 
beneﬁ  cial for emotional and physical well-being, and for 
premenstrual syndrome, which is more common in women 
over the age of 30 (Warner and Bancroft 1990).
Women who use the transdermal contraceptive patch have 
been reported to give higher ratings than oral contraceptive 
users when questioned on their emotional and physical well-
being, and on improvements in premenstrual symptoms. 
In a randomized study comparing the patch with an oral 
contraceptive containing desogestrel and ethinyl estradiol, 
emotional and physical well-being were signiﬁ  cantly higher 
with the patch than with the oral contraceptive, the differ-
ence being clustered in women aged 34 years and over. The 
same difference in improvement of premenstrual symptoms 
(p  0.01) favoring the contraceptive patch was found, once 
again especially in women aged 34 years and over (Urdl 
et al 2005).
These non-contraceptive beneﬁ  cial effects may, at least 
in part, explain the high level of satisfaction reported by 
users of the transdermal patch and may contribute to their 
adherence to treatment.
The perimenopause
The perimenopause is a period lasting up to 5 to 6 years 
during which women experience menstrual cycle changes 
and may also experience typical menopausal signs and 
symptoms, such as bone mineral density loss, vasomotor 
instability, and joint pain. Some women erroneously believe 
that they no longer need contraception, although statistics 
show that up to 80% of women aged 40 to 44 years can 
conceive (Schmidt-Sarosi 1998). For these women, hormonal 
contraception, which offers protection against undesired 
pregnancy as well as correction of hormonal imbalance, is 
more suitable than hormone replacement therapy, which 
offers only the latter (Kaunitz 2001).
In hormonal combinations, contraceptives containing 
norgestimate have demonstrated prominent changes in 
bone resorption and formation markers in patients with 
hypothalamic amenorrhea, a young population experiencing 
signiﬁ  cant bone loss (Grinspoon et al 2003). These ﬁ  ndings 
suggest that suitable hormonal combinations can decrease 
the rate of bone turnover and attenuate bone loss in at risk Patient Preference and Adherence 2008:2 365
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populations, such as perimenopausal women (appropriate 
calcium and vitamin D daily intake must be checked and 
integrated if necessary).
In conclusion, in a mutual decision making process with 
their physician, healthy perimenopausal women can be assured 
that the transdermal patch is a useful and reliable contraceptive 
method, and an alternative to oral formulations, which can 
improve perimenopausal symptoms, reduce some long-term 
health risks, and enhance quality of life (Kaunitz 2001).
Satisfaction with the transdermal 
patch
Because human behavior tends to be repeated when rewarded, 
satisfaction with a contraceptive method is essential for long-
term adherence, and depends mainly on selecting the optimal 
contraceptive for the couple (Table 3).
A large European study compared patient attitudes 
(satisfaction and preference) toward the transdermal contracep-
tive patch and toward previous contraceptive methods. Of all 
the women surveyed, 88% said that they were satisﬁ  ed or very 
satisﬁ  ed with the patch and 70.1% preferred the patch to their 
previous method of contraception, which in 72.4% had been 
an oral contraceptive. The main reasons for this preference 
were: convenience (40.9%), ease of use/simplicity (31.5%), 
and fewer side effects (19.3%) (Jakimiuk et al 2006b).
In another similar study 74.9% of women preferred 
the patch, mainly because of its convenience (50.2%) and 
simplicity (32.5%); 91% were satisﬁ  ed or very satisﬁ  ed with 
the patch (Weisberg et al 2005).
Another clinical study showed that patch users were 
signiﬁ  cantly more satisﬁ  ed with their contraceptive than 
users of oral contraceptives (p = 0.001), and that satisfaction 
was associated with duration of use and mental well-being 
(Wan et al 2007).
Patch users sometimes refer to inconveniences, which can 
depend either on the transdermal route of administration or 
on the hormonal mode of action. These include application 
site reactions or pruritus, mainly in subjects with irritated 
or sensitive skin (but 2% of participants discontinued 
treatment for this reason), incomplete adhesive reliability 
(although only a minimal proportion of patches requires 
replacement), patch visibility (which is a problem for only 
a limited subset of subjects; applying the patch to the but-
tock or to lower abdomen guarantees discretion), appearance 
of a dark ring around the patch (probably due to adhesive 
components; washing the area normally where the patch is 
attached could resolve this inconvenience), unpredictable 
vaginal bleeding (an adverse event, common even with oral 
contraceptives, which generally decreased over time) (Audet 
et al 2001; Sibai et al 2002). Therefore, a further optimiza-
tion of structural support and hormones of the patch could 
help improve esthetics and cutaneous tolerability, and reduce 
breakthrough bleeding or spotting.
Conclusions
The transdermal EE/NGMN contraceptive patch is an 
excellent choice for women of any age who desire conve-
nient, easy-to-use, reversible, hormonal contraception. The 
contraceptive efﬁ  cacy of the patch is comparable with that 
of oral contraceptives while adherence and persistence of 
use are consistently better for the patch in all age groups. 
The patch enables a contraceptive to be tailored to suit the 
needs of women of all ages and characteristics. Combined 
with a valuable doctor-patient relationship which permits 
the development of a therapeutic alliance, the patch has 
received higher satisfaction ratings in addition to ensuring 
effectiveness and safety.
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